PVLA: Pieris Pharmaceuticals Inc Price to Sales
The resilience of Pieris Pharmaceuticals (PVLA) is based on the optimization of its development portfolio and payments from strategic partners. The P/S trajectory confirms the market valuation of assets, where the indicator value reaches 821.20. Business flexibility is ensured by outsourcing testing and production to external contractors, while high R&D efficiency is supported by the pristine condition of laboratory equipment and regular instrument maintenance.
Metric breakdowns and analytics for Pieris Pharmaceuticals Inc (PVLA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Capital Pieris Pharmaceuticals|PVLA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Pieris Corp|PVLA - Company Aggregate Debts|Debts to Net Assets Pieris Pharmaceuticals Inc|PVLA - Company Long-Term Debt|Short-Term Debt Volume Pieris Pharmaceuticals|Intermediate Coverage Ratio pieris.com
- earnings and valuation multiples indicators:
PVLA - Company Net Income|Forward Earnings Pieris Pharmaceuticals|PVLA - P/E Multiple|Future Price to Earnings Multiple Pieris Pharma|PVLA - PEG Multiple|EV/EBITDA Multiple Pieris Pharmaceuticals Inc|PVLA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Pieris Pharmaceuticals|PVLA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months pieris.com|PVLA - Earnings growth in current year|Earnings growth forecast for next year Pieris Pharmaceuticals
- issuer revenue and sales details:
General company analysis:PVLA, pieris.com
The P/S multiple compares a business's market value to its annual revenue, allowing for an assessment of the premium paid per unit of revenue and the identification of fundamental imbalances. By analyzing the capitalization-to-revenue ratio, an investor will see that current levels reflect a period of stagnation, as the market has already priced in past partnership failures, while new clinical pipeline drivers for Pieris Pharmaceuticals (PVLA) have not yet begun to impact the valuation.
Competitors of Pieris Pharmaceuticals
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Sales Ratio PTGX|IMVT: P/S Multiple|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|DNTH - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Pharvaris NV PHVS|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Precigen, Inc.|pharming.com - Price-to-Sales Ratio|P/S Multiple NKTR|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|P/S Multiple Immunome Bio IMNM|GOSS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Savara Inc|RIGL (Rigel Pharmaceuticals Inc) - P/S Multiple|P/S Multiple AnaptysBio Inc.|P/S Multiple ATXS|Market Cap to Revenue engene.com ENGN|P/S Multiple RAPT (RAPT Therapeutics)|Aerovate Therapeutics, Inc. (JBIO) - Price to Sales|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|TLSA (Tiziana Life Sciences) - Market Cap to Revenue|CABA: Market Cap to Sales Volume|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Theratechnologies, Inc. (THTX) - Price-to-Revenue Coefficient|P/S Multiple AVTX|Market Cap to Revenue Eledon Pharmaceuticals, Inc ELDN|P/S Multiple AGEN (Agenus)|P/S Multiple climbbio.com CLYM|ZURA - Price-to-Revenue Ratio|ATYR: Price-to-Revenue Ratio|adagene.com (ADAG) - Price-to-Revenue Ratio|IMA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Shattuck Labs Inc|Equillium Bio - Price-to-Sales Ratio|Market Cap to Revenue CNTB (Connect Biopharma)|Price-to-Revenue Ratio IMUX (immunic-therapeutics.com)|Price-to-Revenue Ratio Atara Bio ATRA|InflaRx NV - Price-to-Revenue Ratio|X4 Pharmaceuticals - P/S Multiple|ACET - P/S Multiple|celularity.com (CELU) - Price-to-Revenue Ratio|Price-to-Sales Ratio INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - P/S Multiple|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|Market Capitalization-to-Revenue Ratio QTTB|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Market Cap to Revenue XTLB|BOLT: Market Capitalization-to-Revenue Ratio|P/S Multiple HCWB|Price-to-Revenue Coefficient aptevotherapeutics.com|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|P/S Multiple CALI|AFMD - Price to Sales|Price-to-Revenue Ratio Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Price-to-Sales Ratio|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|OCEA: P/S Multiple|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Price-to-Revenue Ratio Third Harmonic Bio, Inc
